SALT LAKE CITY — In this video, Jay Chhablani, MD , professor of ophthalmology at University of Pittsburgh School of Medicine, discusses a preliminary study of combination gene therapy targeting neovascular age-related macular degeneration.

The therapy, a combination of AIBP, apoA-I and aflibercept, showed promise in a mouse study presented at the ARVO meeting, Chhablani said.

“This combination of this triple gene therapy may overcome the anti-VEGF resistance as well as improve outcomes,” Chhablani said.

Reference:

Ahir M, et al. Combination gene therapy of AIBP, apoA-I, and aflibercept overcomes anti-VEGF resistance and suppresses fibrosis in neovascular AMD. Presented at: Association for Research in Vision and Ophthalmology meeting; May 4-8, 2025; Salt Lake City.

See Full Page